Syna Therapeutics, a joint venture of Reig Jofre and Leanbio, today announces that it has signed a global licensing deal with Intas Pharmaceuticals Ltd. to commercialise its biosimilar drug LB-0702 to treat pathologies in the field of haematology.
Andreu Soldevila, CEO of Syna, Gabriel Roig, chairman of the Syna Board,
and Isabel Amat, member of the Syna Board
Syna Therapeutics, a joint venture of Reig Jofre and Leanbio, today announces that it has signed a global licensing deal with Intas Pharmaceuticals Ltd. to commercialise its biosimilar drug LB-0702 to treat pathologies in the field of haematology.
Under the terms of the agreement, Intas have been granted exclusive license rights to commercialise LB-0702 worldwide, and Syna will develop and manufacture LB-0702 and supply the product to Intas and its affiliates. As one of the key players in the global biosimilar market, Accord Healthcare, Intas’ wholly owned subsidiary, has proven commercial capabilities with one of the latest sales and distribution networks in 85 countries.
Syna will begin clinical trials for LB-0702 in 2023 with support from its partners Leanbio and Reig Jofre. Utilising the technology platforms of Leanbio coupled with the technology production expertise of Reig Jofre at its new manufacturing plant in Barcelona (Spain) purposed for sterile injectables and lyophilised biopharmaceutical products.
“Signing this deal is one of Syna’s most important milestones since the company was founded in 2018 and it confirms the pharmaceutical industry and healthcare systems’ growing interest in biosimilar drugs,” notes Dr Andreu Soldevila, co-founder and CEO of Syna. “We are delighted with this agreement with Intas because we believe biosimilar LB-0702 will have a very positive impact to healthcare systems. Accord Healthcare, Intas’ wholly owned subsidiary, is the ideal partner to commercialise our biosimilar in global markets” says Soldevila.
Binish Chudgar, Vice Chairman and Managing Director of Intas, commented “we are pleased to announce this agreement with Syna. This agreement sets out Accord Healthcare to file for global rights to this critical drug and is in line with our long-term strategy, reinforcing our commitment to improving access to high-quality biosimilar drugs for patients globally.”
Founded in 2018, Syna Therapeutics develops high quality biosimilars and innovative molecules to respond to the growing global demand for biological treatments. The company has extensive experience and know-how in all phases of biosimilar medicines, covering the entire value chain to enable biosimilars to reach patients: cell bank creation, pharma development of the finished product, industrial production, and marketing or license agreements. Its headquarters are at the Barcelona Science Park.
Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad (India), having end-to-end capabilities of formulation development, manufacturing and marketing along with backward integration of APIs. The organisation has more than 18,000 employees and 14 manufacturing sites worldwide. The Intas Group’s revenue amounted to USD 2.5 bn in FY 2021-22 and the compounded annual growth rate of revenue has been 22% in the past 5 years.